Aspirus Regional Cancer Center

Cancer Clinical Trials

This is a current listing of active clinical trials at the Aspirus Regional Cancer Center. From this list you can select a specific cancer that you are interested in (for example, breast or colon cancer) and then review the clinical trials that are active at the Aspirus Regional Cancer Center for that specific disease.

Lymphoma

Trial Name: A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs. Bortezomib-BR (BVR) Followed by Rituximab vs. BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma.

Protocol ID: ECOG - 2408

Eligibility:

  • Patient must have a histologically confirmed (biopsy-proven) diagnosis of follicular B-cell non-Hodgkin’s lymphoma with no evidence of transformation to large cell histology.
  • Patient must meet required laboratory values.
  • Patient must have had no prior chemotherapy, radiotherapy or immunotherapy for lymphoma. For purposes of this trial, prednisone or other corticosteroids used for non-lymphomatous conditions will not be considered as prior chemotherapy.
  • Patient must have no recent history of malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for at least 2 years.
  • Patients must not have known hypersensitivity to boron or mannitol.
  • Age 18 years or older.
  • Women must not be pregnant or breast-feeding due to use of chemotherapy and experimental treatment agents in this protocol. 

Men and women of childbearing potential must use reliable forms of birth control or practice complete abstinence at certain time points: before, during, and after study treatment.

Enrollment: • About 250 people will take part in this study at several medical centers.

Benefits:

Taking part in this study may or may not make your health better. While doctors hope rituximab-bendamustine in combination with bortezomib and/or rituximab combined with lenalidomide will be more useful against your lymphoma compared to the usual treatment, there is no proof of this yet. We do know that the information from this study will help doctors learn more about these drugs as a treatment for cancer. This information could help future cancer patients.

Contact:

These clinical trial overviews are intended to provide a brief overview of the clinical trial. To help determine whether the trial is appropriate for you, the major eligibility criteria are listed above. To obtain more information on the eligibility and the treatment plan, please contact our Oncology Clinical Research Coordinator, Beth Knetter at 715-847-2353 or 1-800-283-2881, ext.72353.

Created: Jun 3, 2011

Updated: Jan 18, 2013

« Return to Trials